Maas_2017_Ann.Neurol_82_1004

Reference

Title : Progressive deafness-dystonia due to SERAC1 mutations: A study of 67 cases - Maas_2017_Ann.Neurol_82_1004
Author(s) : Maas RR , Iwanicka-Pronicka K , Kalkan Ucar S , Alhaddad B , AlSayed M , Al-Owain MA , Al-Zaidan HI , Balasubramaniam S , Baric I , Bubshait DK , Burlina A , Christodoulou J , Chung WK , Colombo R , Darin N , Freisinger P , Garcia Silva MT , Grunewald S , Haack TB , van Hasselt PM , Hikmat O , Horster F , Isohanni P , Ramzan K , Kovacs-Nagy R , Krumina Z , Martin-Hernandez E , Mayr JA , McClean P , de Meirleir L , Naess K , Ngu LH , Pajdowska M , Rahman S , Riordan G , Riley L , Roeben B , Rutsch F , Santer R , Schiff M , Seders M , Sequeira S , Sperl W , Staufner C , Synofzik M , Taylor RW , Trubicka J , Tsiakas K , Unal O , Wassmer E , Wedatilake Y , Wolff T , Prokisch H , Morava E , Pronicka E , Wevers RA , de Brouwer AP , Wortmann SB
Ref : Annals of Neurology , 82 :1004 , 2017
Abstract :

OBJECTIVE: 3-Methylglutaconic aciduria, dystonia-deafness, hepatopathy, encephalopathy, Leigh-like syndrome (MEGDHEL) syndrome is caused by biallelic variants in SERAC1. METHODS: This multicenter study addressed the course of disease for each organ system. Metabolic, neuroradiological, and genetic findings are reported. RESULTS: Sixty-seven individuals (39 previously unreported) from 59 families were included (age range=5 days-33.4 years, median age=9 years). A total of 41 different SERAC1 variants were identified, including 20 that have not been reported before. With the exception of 2 families with a milder phenotype, all affected individuals showed a strikingly homogeneous phenotype and time course. Severe, reversible neonatal liver dysfunction and hypoglycemia were seen in >40% of all cases. Starting at a median age of 6 months, muscular hypotonia (91%) was seen, followed by progressive spasticity (82%, median onset=15 months) and dystonia (82%, 18 months). The majority of affected individuals never learned to walk (68%). Seventy-nine percent suffered hearing loss, 58% never learned to speak, and nearly all had significant intellectual disability (88%). Magnetic resonance imaging features were accordingly homogenous, with bilateral basal ganglia involvement (98%); the characteristic "putaminal eye" was seen in 53%. The urinary marker 3-methylglutaconic aciduria was present in virtually all patients (98%). Supportive treatment focused on spasticity and drooling, and was effective in the individuals treated; hearing aids or cochlear implants did not improve communication skills. INTERPRETATION: MEGDHEL syndrome is a progressive deafness-dystonia syndrome with frequent and reversible neonatal liver involvement and a strikingly homogenous course of disease. Ann Neurol 2017;82:1004-1015.

PubMedSearch : Maas_2017_Ann.Neurol_82_1004
PubMedID: 29205472
Gene_locus related to this paper: human-SERAC1

Related information

Mutation X655Lext32_human-SERAC1    S608T_human-SERAC1    V556D_human-SERAC1    c.1403+4A>G_human-SERAC1    W410R_human-SERAC1    V371AfsX22_human-SERAC1    Q315RfsX4_human-SERAC1    R306X_human-SERAC1    P258MfsX22_human-SERAC1    R31KfsX3_human-SERAC1    R183X_human-SERAC1    R31X_human-SERAC1    R447X_human-SERAC1    196-211del_human-SERAC1    G339R_human-SERAC1    Y548X_human-SERAC1    L550SfsX19_human-SERAC1    R368X_human-SERAC1    L193Sfs_human-SERAC1
Gene_locus X655Lext32_human-SERAC1    S608T_human-SERAC1    V556D_human-SERAC1    c.1403+4A>G_human-SERAC1    W410R_human-SERAC1    V371AfsX22_human-SERAC1    Q315RfsX4_human-SERAC1    R306X_human-SERAC1    P258MfsX22_human-SERAC1    R31KfsX3_human-SERAC1    R183X_human-SERAC1    R31X_human-SERAC1    R447X_human-SERAC1    196-211del_human-SERAC1    G339R_human-SERAC1    Y548X_human-SERAC1    L550SfsX19_human-SERAC1    R368X_human-SERAC1    L193Sfs_human-SERAC1    human-SERAC1
Disease X655Lext32_human-SERAC1    S608T_human-SERAC1    V556D_human-SERAC1    c.1403+4A>G_human-SERAC1    W410R_human-SERAC1    V371AfsX22_human-SERAC1    Q315RfsX4_human-SERAC1    R306X_human-SERAC1    P258MfsX22_human-SERAC1    R31KfsX3_human-SERAC1    R183X_human-SERAC1    R31X_human-SERAC1    R447X_human-SERAC1    196-211del_human-SERAC1    G339R_human-SERAC1    Y548X_human-SERAC1    L550SfsX19_human-SERAC1    R368X_human-SERAC1    L193Sfs_human-SERAC1    human-SERAC1    MEGDEL syndrome

Citations formats

Maas RR, Iwanicka-Pronicka K, Kalkan Ucar S, Alhaddad B, AlSayed M, Al-Owain MA, Al-Zaidan HI, Balasubramaniam S, Baric I, Bubshait DK, Burlina A, Christodoulou J, Chung WK, Colombo R, Darin N, Freisinger P, Garcia Silva MT, Grunewald S, Haack TB, van Hasselt PM, Hikmat O, Horster F, Isohanni P, Ramzan K, Kovacs-Nagy R, Krumina Z, Martin-Hernandez E, Mayr JA, McClean P, de Meirleir L, Naess K, Ngu LH, Pajdowska M, Rahman S, Riordan G, Riley L, Roeben B, Rutsch F, Santer R, Schiff M, Seders M, Sequeira S, Sperl W, Staufner C, Synofzik M, Taylor RW, Trubicka J, Tsiakas K, Unal O, Wassmer E, Wedatilake Y, Wolff T, Prokisch H, Morava E, Pronicka E, Wevers RA, de Brouwer AP, Wortmann SB (2017)
Progressive deafness-dystonia due to SERAC1 mutations: A study of 67 cases
Annals of Neurology 82 :1004

Maas RR, Iwanicka-Pronicka K, Kalkan Ucar S, Alhaddad B, AlSayed M, Al-Owain MA, Al-Zaidan HI, Balasubramaniam S, Baric I, Bubshait DK, Burlina A, Christodoulou J, Chung WK, Colombo R, Darin N, Freisinger P, Garcia Silva MT, Grunewald S, Haack TB, van Hasselt PM, Hikmat O, Horster F, Isohanni P, Ramzan K, Kovacs-Nagy R, Krumina Z, Martin-Hernandez E, Mayr JA, McClean P, de Meirleir L, Naess K, Ngu LH, Pajdowska M, Rahman S, Riordan G, Riley L, Roeben B, Rutsch F, Santer R, Schiff M, Seders M, Sequeira S, Sperl W, Staufner C, Synofzik M, Taylor RW, Trubicka J, Tsiakas K, Unal O, Wassmer E, Wedatilake Y, Wolff T, Prokisch H, Morava E, Pronicka E, Wevers RA, de Brouwer AP, Wortmann SB (2017)
Annals of Neurology 82 :1004